Immunization with matrix-, nucleoprotein and neuraminidase protects against H3N2 influenza challenge in pH1N1 pre-exposed pigs.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
15 Feb 2023
15 Feb 2023
Historique:
received:
13
09
2022
accepted:
30
01
2023
entrez:
15
2
2023
pubmed:
16
2
2023
medline:
16
2
2023
Statut:
epublish
Résumé
There is an urgent need for influenza vaccines providing broader protection that may decrease the need for annual immunization of the human population. We investigated the efficacy of heterologous prime boost immunization with chimpanzee adenovirus (ChAdOx2) and modified vaccinia Ankara (MVA) vectored vaccines, expressing conserved influenza virus nucleoprotein (NP), matrix protein 1 (M1) and neuraminidase (NA) in H1N1pdm09 pre-exposed pigs. We compared the efficacy of intra-nasal, aerosol and intra-muscular vaccine delivery against H3N2 influenza challenge. Aerosol prime boost immunization induced strong local lung T cell and antibody responses and abrogated viral shedding and lung pathology following H3N2 challenge. In contrast, intramuscular immunization induced powerful systemic responses and weak local lung responses but also abolished lung pathology and reduced viral shedding. These results provide valuable insights into the development of a broadly protective influenza vaccine in a highly relevant large animal model and will inform future vaccine and clinical trial design.
Identifiants
pubmed: 36792640
doi: 10.1038/s41541-023-00620-2
pii: 10.1038/s41541-023-00620-2
pmc: PMC9930017
doi:
Types de publication
Journal Article
Langues
eng
Pagination
19Subventions
Organisme : Pirbright Institute
ID : BBS/E/I/00007037
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/I/00007031
Pays : United Kingdom
Organisme : RCUK | Medical Research Council (MRC)
ID : MR/S037160/1
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/I/00007037
Pays : United Kingdom
Organisme : Pirbright Institute
ID : BBS/E/I/00007039
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/I/COV07001
Pays : United Kingdom
Organisme : Pirbright Institute
ID : BBS/E/I/00007031
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/I/00007039
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s).
Références
Mol Ther. 2014 Mar;22(3):668-674
pubmed: 24374965
J Clin Invest. 2008 Oct;118(10):3273-5
pubmed: 18802488
J Virol. 2021 Aug 10;95(17):e0075921
pubmed: 34160258
J Virol. 2021 Jan 28;95(4):
pubmed: 33268518
Vet Pathol. 2014 Mar;51(2):410-26
pubmed: 24363301
ILAR J. 2015;56(1):44-52
pubmed: 25991697
Vet Pathol. 2012 Nov;49(6):900-12
pubmed: 22461226
Sci Rep. 2013;3:1443
pubmed: 23485942
Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20748-53
pubmed: 22143798
Lancet Infect Dis. 2021 Dec;21(12):1654-1664
pubmed: 34324836
Vaccine. 2005 May 25;23(28):3634-41
pubmed: 15882523
Curr Top Microbiol Immunol. 2015;386:301-21
pubmed: 25007847
J Immunol. 2021 Feb 1;206(3):652-663
pubmed: 33328212
J Infect Dis. 2011 Sep 15;204(6):845-53
pubmed: 21846636
Vaccine. 2017 Jan 23;35(4):639-646
pubmed: 28041780
Am J Respir Crit Care Med. 2015 Jun 15;191(12):1422-31
pubmed: 25844934
Vet Res. 2016 Oct 20;47(1):103
pubmed: 27765064
Clin Infect Dis. 2012 Jul;55(1):19-25
pubmed: 22441650
Sci Transl Med. 2020 Dec 9;12(573):
pubmed: 33298562
Immunol Rev. 2020 Jul;296(1):191-204
pubmed: 32666572
Nat Med. 2012 Jan 29;18(2):274-80
pubmed: 22286307
Lancet Infect Dis. 2014 Oct;14(10):939-46
pubmed: 25151225
Sci Transl Med. 2021 Aug 18;13(607):
pubmed: 34315826
mBio. 2019 May 21;10(3):
pubmed: 31113896
mBio. 2018 Apr 3;9(2):
pubmed: 29615508
Front Immunol. 2022 Jun 09;13:903755
pubmed: 35757698
Curr Opin Virol. 2013 Oct;3(5):521-30
pubmed: 23978327
Front Immunol. 2021 Nov 03;12:763912
pubmed: 34804053
Vaccines (Basel). 2019 May 15;7(2):
pubmed: 31096710
JCI Insight. 2022 Feb 8;7(3):
pubmed: 34990408
Lancet Respir Med. 2022 Aug;10(8):739-748
pubmed: 35605625
Nat Med. 2013 Oct;19(10):1305-12
pubmed: 24056771
mBio. 2021 Dec 21;12(6):e0224121
pubmed: 34809451
N Engl J Med. 1983 Jul 7;309(1):13-7
pubmed: 6602294
Cell Host Microbe. 2019 Dec 11;26(6):712-713
pubmed: 31951584
J Med Virol. 2002 Aug;67(4):589-95
pubmed: 12116009
Nat Immunol. 2017 Apr;18(4):464-473
pubmed: 28192418
J Virol. 2020 Jan 31;94(4):
pubmed: 31748388
EBioMedicine. 2018 Mar;29:146-154
pubmed: 29519670
J Immunol. 2018 Jun 15;200(12):4068-4077
pubmed: 29703861
N Engl J Med. 2015 Apr 16;372(16):1519-29
pubmed: 25875257
Expert Rev Vaccines. 2007 Apr;6(2):213-26
pubmed: 17408371
Future Virol. 2016 Sep;11(9):649-659
pubmed: 29527232
Expert Rev Vaccines. 2004 Dec;3(6):643-54
pubmed: 15606348
Vet Pathol. 1995 Nov;32(6):648-60
pubmed: 8592800
mBio. 2021 Oct 26;12(5):e0190821
pubmed: 34544278
J Infect Dis. 2020 Aug 4;222(5):807-819
pubmed: 31740938
J Immunol. 2016 Jun 15;196(12):5014-23
pubmed: 27183611
Front Immunol. 2020 Oct 27;11:594470
pubmed: 33193445
Viruses. 2020 Sep 17;12(9):
pubmed: 32957468